Phuturdex › Diseases › Metabolic disease
Drugs in development · updated 30 October 2026
Metabolic disease: drugs in development
As of 30 October 2026 there are 35 active clinical trials (recruiting or ongoing, phases I–III) on 30 drugs for metabolic disease. 22 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Pegozafermin | III | 2 | NCT06419374 |
| PF-08653944 | III | 2 | NCT07595549 |
| Retatrutide | III | 2 | NCT06260722 |
| Berobenatide | III | 1 | NCT07874633 |
| ECUR-506 | III | 1 | NCT06255782 |
| Encaleret | III | 1 | NCT05680818 |
| ErsodetugRZ358 | III | 1 | NCT06208215 |
| GNR-055 | II–III | 1 | NCT05208281 |
| Zodasiran | III | 1 | NCT07473843 |
| 4D-310 | I–II | 2 | NCT05629559 |
| MRNA-3927 | I–II | 2 | NCT05130437 |
| AMX0035 | II | 1 | NCT07699380 |
| Diamyd | II | 1 | NCT05683990 |
| FBX-101 | I–II | 1 | NCT05739643 |
| KK8123 | I–II | 1 | NCT06525636 |
| Puerarin | II | 1 | NCT06968208 |
| BLX-0871 | I | 1 | NCT07140081 |
| BLX-7006 | I | 1 | NCT07140055 |
| CTX310 | I | 1 | NCT07491172 |
| HRS-1597 | I | 1 | NCT07808918 |
| IN026 | I | 1 | NCT07587684 |
| SNS851 | I | 1 | NCT07417124 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MitapivatAG-348, Pyrukynd® | III | 2 | NCT05144256 |
| LerodalcibepLyrokaul® | III | 1 | NCT06568471 |
| OrforglipronFoundayo® | III | 1 | NCT07613307 |
| SemaglutideWegovy, Rybelsus | III | 1 | NCT06260722 |
| TirzepatideZepbound, Mounjaro | II | 2 | NCT06820281 |
| Sacubitril | II | 1 | NCT04055428 |
| ValsartanPrexxartan®, Diovan® | II | 1 | NCT04055428 |
| VericiguatVerquvo® | II | 1 | NCT06320951 |
Sorted by most advanced phase and number of active trials.
All 30 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Type 2 diabetes 171 drugs
- Type-1 diabetes 80 drugs
- Diabetes 91 drugs
- Amyotrophic lateral sclerosis 79 drugs
- Obesity 233 drugs
- Overweight 139 drugs
- Insulin resistance 41 drugs
- Immunoglobulin Light-chain Amyloidosis 27 drugs
- Hyperlipidemia 26 drugs
- Amyloidosis 24 drugs
- Dyslipidemia 35 drugs
- Hypercholesterolemia 21 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Nutrition disorder 10 drugs
- Metabolism, Inborn Errors 6 drugs
- Overweight 139 drugs
- Overnutrition 5 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008659 “Metabolic Diseases”.